Session: P-71. Treatment of Antimicrobial Resistant Infections

Background. Aspergillus fumigatus is the leading cause of invasive aspergillosis (IA), a lethal infection among immunocompromised patients. Guidelines recommend antifungal therapy against IA is a triazole antifungal, with other secondary options including an echinocandin and amphotericin B. Concerns about drug-host toxicity and antifungal resistance have been globally reported, so new, safe, and effective therapeutics are imperative.

Methods. In vitro, CLSI standards were upheld as we tested APX2041, voriconazo- 
line, caspofungin, and amphotericin B against various A. fumigatus strains. In vivo we assessed toxicity and efficacy of APX2041 in immunocompromised mice respectively.

Conclusion. We assessed the in vivo efficacy and toxicity of APX2041 in immunocompromised mice respectively. Neutropenia was induced with 150 mg/kg of cyclophosphamide on days -2/3 and 250 mg/kg of cortisone acetate on days -1/6. Immunosuppressed mice were infected in an inhalation chamber via 12 mL of aerosolized spores of A. fumigatus CEA10 at a concentration of 1x10^6 spores/mL (Day 0). Treatment started day +1 and ended day +7.

Results. In vitro, APX2041, the active form of APX2041, has over a 16-fold lower minimum effective concentration (MIC) when compared to voriconazole, caspo-
fungin, and amphotericin B against various A. fumigatus strains, including echinocan-
din- and azole-resistant strains.

Conclusion. Future studies will test the efficacy of APX2041 and posaconazole against azole antifungal resistant strains in vivo, as our preliminary findings sug-
gest that APX2041 is a plausible solution to cure IA disease and combat antifungal resistance.

Disclosures. All Authors: No reported disclosures

161. Mechanism of Thrombocytopenia Induced by Oxazolidinones Antibiotics (Linezolid, Tedizolid): Demonstration of Impairment of Megakaryocyte Differentiation From Human Hematopoietic Stem Cells associated with Mitochondrial Toxicity

Paul M. Tulkens, MD, PhD1; Tamara V. Milosevic, PhD2; Gaëlle Vertenoele, MD1; William Vainchenker, MD, PhD; Stefan N. Constantinescu, MD, PhD; François Van Bambeke, PharmD, PhD2; Université catholique de Louvain, Brussels, Brussels Hoofdstedelijk Gewest, Belgium; l’Université de Paris-Sud, Villejuif, Île-de-France, France

Background. Linezolid causes thrombocytopenia, which limits its use. In cell culture and in vivo, thrombocytopenia is associated with mitochondrial protein synthesis (due to structural similarities and common binding sites between bacterial and mitochondrial ribosomes). Recent studies have shown that mitochondria act as a key relay in the process leading from activation of the thrombopoietin receptor to megakaryocytes differentiation.

Methods. Validated ex-vivo human model of hematopoietic stem cells (HSC) differentiation for (i) measuring megakaryocytes, granulocyte-monocytes, and burst-forming unit-erythroid colonies formation; (ii) differentiation into megakaryo-

Conclusion. Our study provides for the first time in vivo insights in the mechanism of thrombocytopenia induced by linezolid and tedizolid, identifying mitochondria as their target and showing that the drugs will impair the differentiation of hematopoietic stem cells into mature platelets-releasing megakaryocytes. It illustrates how mitochondrial dysfunction may play a key role in toxicology and diseases, while paving the way for rationalized strategies for the design and screening of less toxic derivatives for the benefit of future patients.

Disclosures. Paul M. Tulkens, MD, PhD, Bayer (Consultant, Advisor or Review Panel member, Speaker's Bureau)Menarini (Advisor) Merck (Advisor or Review Panel member, Speaker's Bureau)Bambeke, François Van (Research Grant or Support)

1617. Mecillinam susceptibility against Enterobacteriaceae isolated from urinary tract infections from US patients in 2018

Stephen Hawser, PhD1; Ian Morrissey2; Cedric Charrier, PhD2; Cynthia De Piano, PhD1; Jonathan Alexander, PhD3; Anne Santenen Hensrud, MS1; IHHMA, Monthy, Valais, Switzerland; IHHMA, Europe, Monthy, Valais, Switzerland; Utility, Therapeutics, London, England, United Kingdom; 4Maxel Consulting ApS, London, England, United Kingdom

Session: P-71. Treatment of Antimicrobial Resistant Infections

Background. Mecillinam is a unique amidopenicillin antibiotic, being the first and the only compound in its class. In contrast to other beta-lactams, it has a unique mechanism of action whereby it exerts its antibacterial activity through binding to penicillin binding protein 2. Fosfomycin is the oral prodrug of mecillinam and rec-

Methods. Histology samples also demonstrated that APX2104 treatment slowed down the fusion of both complicated UTI and uUTI this study investigated the activity of mecillinam on different antifungal resistance have been globally reported, so new, safe, and effective therapeutics are imperative.

Session: S-71. Treatment of Antimicrobial Resistant Infections

Background. Mecillinam susceptibility against Enterobacteriaceae isolated from urinary tract infections from US patients in 2018

Overall, mecillinam showed the lowest MIC values when compared to the untreated group. When compared to the untreated group, H&E and GMS histological samples also demonstrated that APX2104 treatment slowed down the fusion of both complicated UTI and uUTI this study investigated the activity of mecillinam on different antifungal resistance have been globally reported, so new, safe, and effective therapeutics are imperative.

Conclusion. Our study provides for the first time in vivo insights in the mechanism of thrombocytopenia induced by linezolid and tedizolid, identifying mitochondria as their target and showing that the drugs will impair the differentiation of hematopoietic stem cells into mature platelets-releasing megakaryocytes. It illustrates how mitochondrial dysfunction may play a key role in toxicology and diseases, while paving the way for rationalized strategies for the design and screening of less toxic derivatives for the benefit of future patients.

Disclosures. Paul M. Tulkens, MD, PhD, Bayer (Consultant, Advisor or Review Panel member, Speaker's Bureau)Menarini (Advisor) Merck (Advisor or Review Panel member, Speaker's Bureau)Bambeke, François Van (Research Grant or Support)